Bioequivalence study of an open-label, randomized, two-way crossover design with two-period, two-treatment, two-sequence of test product lynestrenol 0.5 mg tablets and reference product (ExlutonÂ®) in healthy Thai female volunteers under fasting cond

Start Date01 Mar 2021

Sponsor / Collaborator

Chiang Mai University

[+1]

NCT02715232

/ Unknown statusPhase 4IIT

Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET

The aim of this study is to prove the modulatory influence of sex hormones on serotonergic neurotransmission by determining the enzymatic processes involved in serotonin synthesis and degradation using positron emission tomography (PET) in humans in vivo with the radiotracers [11C]AMT and [11C]harmine.

Start Date06 Feb 2017

Sponsor / Collaborator

Medical University of Vienna

NCT01065220

/ CompletedPhase 4IIT

The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography

The aim of this study is to prove the influence of the sex steroid hormones estrogen, progesterone and testosterone on the serotonin transporter (5-HTT) binding using positron emission tomography (PET) and the selective radioligand [11C]DASB. Specifically, the 5-HTT binding will be quantified before and after hormone therapy underwent by 10 male-to-female (MtF) and 10 female-to-male (FtM) transsexuals urging for hormone treatment. The high-level, long-term administration of opsite sex steroid hormones in transsexuals provide the unique opportunity to investigate the influence of sex steroid hormones on the serotonergic system. Since the serotonin transporter serves as a primary target molecule for antidepressant treatment, the results of the study will be of benefit for the assessment of the clinical relevance of estrogen and testosterone as modulatory and neuroactive agents.

Start Date01 Feb 2010

Sponsor / Collaborator

Medical University of Vienna

100 Clinical Results associated with Lynestrenol

100 Translational Medicine associated with Lynestrenol

100 Patents (Medical) associated with Lynestrenol

792

Literatures (Medical) associated with Lynestrenol

01 Oct 2024·European Journal of Dermatology

The effects of gender-affirming testosterone therapy in transgender men on the development of acne, acne severity and the relationship with clinical parameters: a three-year follow-up study

Article

Author: Den Heijer, Martin ; T'Sjoen, Guy ; Fisher, Alessandra D ; Berg, Julia N ; Madsen, Milou C ; Wiepjes, Chantal M ; Rustemeyer, Thomas ; Dreijerink, Koen M A

Acne can result from increased testosterone concentrations after gender-affirming masculinizing testosterone therapy (GATT) initiation. The aim of this study was to determine the prevalence and risk factors of acne and acne severity in transgender individuals while receiving GATT. A prospective multicenter follow-up study (2010-2019) was performed to assess self-reported acne and acne severity, and define risk factors for acne in transgender men during the first three years after initiation of GATT (n=323). Investigated risk factors included: age at initiation of GATT, body mass index (BMI), type of testosterone administration, use of lynestrenol, alcohol use, smoking and serum testosterone concentrations during therapy. The prevalence of moderate/severe acne increased from 11.8% to 39.1% after one year of GATT. Multivariate analyses showed BMI >25 kg/m2 (relative risk [RR]: 1.46; 95% confidence interval [CI]: 1.18-1.80), age: 18-25 years (RR: 1.98; 95% CI: 1.19-3.33), testosterone concentration >10 nmol/L (RR: 1.91; 95%CI: 1.28-2.84) and the presence of acne at baseline (RR: 1.82; 95%CI: 1.47-2.25) to be risk factors for development of moderate/severe acne. Acne is a common side effect of GATT. Risk factors that influence the occurrence of moderate to severe acne in testosterone-treated transgender men are high BMI, younger age at initiation of GATT and testosterone concentrations within or above the target range. These observations could be taken into account when counselling transgender men starting GATT.

01 Aug 2024·Food Research International

Comparative evaluation of the antihyperglycemic effects of three extracts of sea mustard (Undaria pinnatifida): In vitro and in vivo studies

Article

Author: Lee, Sung Min ; Park, Soo-Yeon ; Kim, Ji Yeon

Undaria pinnatifida (UP) contains multiple bioactive substances, such as polyphenols, polysaccharides, and amino acids, which are associated with various biological properties. This study aimed to evaluate the antihyperglycemic effects of three extracts obtained from UP. UP was extracted under three different conditions: a low-temperature water extract at 50 °C (UPLW), a high-temperature water extract at 90 °C (UPHW), and a 70 % ethanol extract (UPE). Nontargeted chemical profiling using high-performance liquid chromatography-triple/time-of-flight mass spectrometry (HPLC-Triple TOF-MS/MS) was conducted on the three UP extracts. Subsequently, α-glucosidase inhibitory (AGI) activity, glucose uptake, and the mRNA expression of sodium/glucose cotransporter 1 (SGLT1) and glucose transporter 2 (GLUT2) were evaluated in Caco-2 cell monolayers. Furthermore, an oral carbohydrate tolerance test was performed on C57BL/6 mice. The mice were orally administered UP at 300 mg/kg body weight (B.W.), and the blood glucose level and area under the curve (AUC) were measured. Compared with glucose, UPLW, UPHW and UPE significantly inhibited both glucose uptake and the mRNA expression of SGLT1 and GLUT2 in Caco-2 cell monolayers. After glucose, maltose, and sucrose loading, the blood glucose levels and AUC of the UPLW group were significantly lower than those of the control group. These findings suggest that UPLW has antihyperglycemic effects by regulating glucose uptake through glucose transporters and can be expected to alleviate postprandial hyperglycemia. Therefore, UPLW may have potential as a functional food ingredient for alleviating postprandial hyperglycemia.

01 Jun 2024·Endocrine and Metabolic Science

Exploring 3D structure of gonadotropin hormone receptor using homology modeling, molecular dynamic simulation and docking studies in rainbow trout, Oncorhynchus mykiss

Author: Saba, KawKabul ; Khan, Sheema Yaqoob ; Shah, Azra ; Sofi, Faisal Rashid ; Rather, Mohd Ashraf ; Ahmad, Ishtiyaq ; Ahmad, Irfan

Reproductive processes in fishes are regulated by the hypothalamic-pituitary-gonadal (HPG) axis, much like in tetrapods.Within this system, Gonadotropin-Releasing Hormone (GnRH) is released by the hypothalamus, binding to GnRH receptors in the pituitary gland and stimulating the secretion of gonadotropin hormones.The current study aimed to analyze the GnRH receptor in Oncorhynchus mykiss (rainbow trout) using a computational and structural biol. approach.The GnRH receptor gene of O. mykiss comprises a nucleotide sequence of 1707 base pairs with an open reading frame of 1251 base pairs, which is responsible for encoding 416 amino acids.It was found that the GnRH receptor contains leucine (L) as the most abundant amino acid.The secondary structure revealed that alpha helixes constitute the largest percentage (36%) with 153 residues, followed by extended strands with 77 residues (17.51%).The GnRH receptor contains 26 neg. charged and 37 pos. charged amino acid residues.The highest hydrophilicity was observed for lysine (K) at position 310, with a value of -3.900, while the highest hydrophobicity was found for leucine (L) at position 290, with a value of 3.80.Mol. docking anal. showed that the most favorable binding energy was observed for Gestrinone (-7.8 kcal/mol).Gestrinone was found to form hydrogen bonds with MET160, LUE245, LUE62, TYR216, and GLN209 residues of GnRH.Moreover, mol. dynamics revealed that the complexes form robust and enduring connections, indicating their structural integrity throughout the simulation.The results of this study provide insights into the protein modeling, mol. docking, and virtual screening of antagonist ligands against the GnRH receptor.Addnl., they may significantly aid in the advancement and improvement of therapeutic strategies targeted at treating various fish reproductive dysfunctions.

100 Deals associated with Lynestrenol

External Link

KEGG	Wiki	ATC	Drug Bank
D01580	Lynestrenol	G03AC02 G03DC03	DB12474

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Contraception	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis